Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director · President | March 15, 2023 | March 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date March 15, 2023 · Filed March 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2033-03-15 | Direct | 169,500 |
Reported balance
After 2023-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-15 · Grant · Acquired 169,500 · Balance 169,500 F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2023 Filed Mar 17, 2023 20:10 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 169,500 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005252 · doc1.xml · derivative · entry 1 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,500 Underlying: Common Stock · 169,500 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:13 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 113,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013867 · doc1.xml · derivative · entry 1 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 56,700 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002889 · doc1.xml · derivative · entry 2 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,700 Underlying: Common Stock · 56,700 shares Expires 2032-02-04 F2 · derivative.exercise_date: 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 226,800 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002889 · doc1.xml · derivative · entry 1 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,800 Underlying: Common Stock · 226,800 shares Expires 2032-02-04 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:03 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001567619-20-020622 · doc1.xml · derivative · entry 1 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-2 Preferred Stock · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 23 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F8 · ownership.nature: Victor Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-2 Preferred Stock · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 22 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F7 · ownership.nature: Dina Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-2 Preferred Stock · Derivative | 21,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 21 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 21,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F6 · ownership.nature: Beigelman and Lozovsky Living Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-1 Preferred Stock · Derivative | 3,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 20 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F8 · ownership.nature: Victor Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-1 Preferred Stock · Derivative | 3,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 19 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F7 · ownership.nature: Dina Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-1 Preferred Stock · Derivative | 50,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 18 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 50,781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F6 · ownership.nature: Beigelman and Lozovsky Living Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries A Preferred Stock · Derivative | 13,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 17 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F8 · ownership.nature: Victor Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries A Preferred Stock · Derivative | 13,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 16 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F7 · ownership.nature: Dina Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries A Preferred Stock · Derivative | 163,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · derivative · entry 15 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 163,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F6 · ownership.nature: Beigelman and Lozovsky Living Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 1,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 14 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F8 · ownership.nature: Victor Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 1,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 13 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F7 · ownership.nature: Dina Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 21,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 12 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 236,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F6 · ownership.nature: Beigelman and Lozovsky Living Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 3,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 11 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 16,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F8 · ownership.nature: Victor Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 3,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 10 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 16,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F7 · ownership.nature: Dina Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 50,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 9 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 214,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F6 · ownership.nature: Beigelman and Lozovsky Living Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 13,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 8 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F8 · ownership.nature: Victor Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 13,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 7 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F7 · ownership.nature: Dina Beigelman Irrevocable Trust. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 163,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018000 · doc1.xml · nonDerivative · entry 6 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 163,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F6 · ownership.nature: Beigelman and Lozovsky Living Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.